https://www.selleckchem.com/products/GDC-0449.html
A double blind clinical trial was performed to evaluate whether the polycystic ovary syndrome (PCOS)-specific serum markers and metabolic parameters would change in the women with PCOS during the three-month administration of oligopin. In this double-blind multicenter trial, we randomly assigned 80 PCOS women, based on a 11 ratio, to receive oligopin (n= 4 or maltodextrin as placebo (n = 4 for upto 3 months. As PCOS-specific outcomes, we investigated the changes in testosterone, sex hormone binding globulin (SHBG), free androgen in
Like
Comment
Share
